{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:46:00Z","timestamp":1771479960815,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s12185-016-2130-z","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T05:12:01Z","timestamp":1478754721000},"page":"309-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis"],"prefix":"10.1007","volume":"105","author":[{"given":"Norio","family":"Komatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohshi","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Amagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Yonezu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"2130_CR1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.23703","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:915\u201325.","journal-title":"Am J Hematol"},{"key":"2130_CR2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905\u201314.","journal-title":"Leukemia"},{"key":"2130_CR3","doi-asserted-by":"crossref","unstructured":"Scherber RM, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. Symptomatic burden in myelofibrosis (MF): prospective international assessment in 128 MF patients. J Clin Oncol. 2011;29(suppl) [abstract 6610].","DOI":"10.1200\/jco.2011.29.15_suppl.6610"},{"key":"2130_CR4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68\u201376.","journal-title":"Cancer"},{"key":"2130_CR5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","volume":"60","author":"OI Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233\u201345.","journal-title":"Annu Rev Med"},{"key":"2130_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ajh.23384","volume":"88","author":"A Tefferi","year":"2013","unstructured":"Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:141\u201350.","journal-title":"Am J Hematol"},{"key":"2130_CR7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199\u2013203.","journal-title":"Leuk Res"},{"key":"2130_CR8","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"2130_CR9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"188","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;188:1723\u201335.","journal-title":"Blood"},{"key":"2130_CR10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391\u2013405.","journal-title":"N Engl J Med"},{"key":"2130_CR11","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","volume":"123","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123:3714\u20139.","journal-title":"Blood"},{"key":"2130_CR12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"2130_CR13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"2130_CR14","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122:4047\u201353.","journal-title":"Blood"},{"key":"2130_CR15","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3109\/10428194.2014.969260","volume":"56","author":"CW Jung","year":"2015","unstructured":"Jung CW, Shih LY, Xiao Z, Jie J, Hou HA, Du X, et al. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. Leuk Lymphoma. 2015;56:2067\u201374.","journal-title":"Leuk Lymphoma"},{"key":"2130_CR16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12185-015-1746-8","volume":"101","author":"K Oritani","year":"2015","unstructured":"Oritani K, Okamoto S, Tauchi T, Saito S, Ohishi K, Handa H, et al. A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis. Int J Hematol. 2015;101:295\u2013304.","journal-title":"Int J Hematol"},{"key":"2130_CR17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013;6:81.","journal-title":"J Hematol Oncol."},{"key":"2130_CR18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015;170:29\u201339.","journal-title":"Br J Haematol"},{"key":"2130_CR19","doi-asserted-by":"crossref","first-page":"848473","DOI":"10.1155\/2015\/848473","volume":"2015","author":"KL Davis","year":"2015","unstructured":"Davis KL, C\u00f4t\u00e9 I, Kaye JA, Mendelson E, Goa H, Perez Ronco J. Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol. 2015;2015:848473.","journal-title":"Adv Hematol"},{"key":"2130_CR20","unstructured":"Giraldo P, Palandri F, Palumbo GA, Zaritskey A, Calistri E, Skotnicki A, et al. Safety and efficacy of ruxolitinib (RUX) in patients with Intermediate-1\u2013risk myelofibrosis (MF) from an open-label, multicenter, single-arm expanded-access study. Haematologica. 2015;100(suppl 1) [abstract P675]."},{"key":"2130_CR21","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937\u201351.","journal-title":"Blood"},{"key":"2130_CR22","doi-asserted-by":"crossref","unstructured":"Tavares R, Palumbo GA, LeCoutre P, Palandri F, Al-Ali H, Martino B, et al. Safety and efficacy of ruxolitinib in an 1869-patient cohort of JUMP: an open-label, multicenter, single-arm, expanded-access study in patients with myelofibrosis. Blood. 2015;126 [abstract 2799].","DOI":"10.1182\/blood.V126.23.2799.2799"},{"key":"2130_CR23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","volume":"94","author":"F Palandri","year":"2015","unstructured":"Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94:519\u201320.","journal-title":"Ann Hematol"},{"key":"2130_CR24","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","volume":"56","author":"YH Chen","year":"2015","unstructured":"Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56:1528\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2130_CR25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00277-013-1936-5","volume":"93","author":"CH Shen","year":"2013","unstructured":"Shen CH, Hwang CE, Chen YY, Chen CC. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol. 2013;93:1075\u20136.","journal-title":"Ann Hematol"},{"key":"2130_CR26","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"RA Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369:681\u20133.","journal-title":"N Engl J Med"},{"key":"2130_CR27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","volume":"369","author":"R Wathes","year":"2013","unstructured":"Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369:197\u20138.","journal-title":"N Engl J Med"},{"key":"2130_CR28","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","volume":"143","author":"NG Wysham","year":"2013","unstructured":"Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel Janus kinase 1,2 inhibitor. Chest. 2013;143:1478\u20139.","journal-title":"Chest"},{"key":"2130_CR29","first-page":"2014","volume":"2","author":"SC Lee","year":"2014","unstructured":"Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014;2:2014.","journal-title":"BMJ Case Rep."},{"key":"2130_CR30","unstructured":"Hultcrantz M, Lund SH, Andersson TM, Bj\u00f6rkholm M, Kristinsson S. Myeloproliferative neoplasms and infections; a population-based study on 9,665 patients with myeloproliferative neoplasms diagnosed in Sweden 1987\u20132009. Haematologica. 2015;100(suppl 1) [abstract P666]."},{"key":"2130_CR31","unstructured":"Polverelli N, Breccia M, Benevolo G, Latagliata R, Catani L, Perricone M, et al. Unfavorable karyotype and molecular negativity significantly influence the infectious risk in myelofibrosis: evaluation on 426 patients. Haematologica. 2015;100(suppl 1) [abstract P667]."},{"key":"2130_CR32","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SA, Daecke SN, Wallner S, Parampalli Yajnanarayana S, Kurts C, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122:1192\u2013202.","journal-title":"Blood"},{"key":"2130_CR33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/leu.2013.296","volume":"28","author":"M Massa","year":"2014","unstructured":"Massa M, Rosti V, Campanelli R, Fois G, Barosi G. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. Leukemia. 2014;28:449\u201351.","journal-title":"Leukemia"},{"key":"2130_CR34","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberg K, Rudolph J, Cornez I, Brossart P, Wolf D. The JAK1\/JAK2 inhibitor ruxolitinib substantially affects NK cell biology. Blood. 2013;122 [abstract 16].","DOI":"10.1182\/blood.V122.21.16.16"},{"key":"2130_CR35","doi-asserted-by":"crossref","unstructured":"Griesshammer M, Vannucchi A, le Coutre P, Tavares R, Al-Ali H, Raanani P, et al. Safety and efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF). Blood. 2014;124 [abstract 1859].","DOI":"10.1182\/blood.V124.21.1859.1859"}],"updated-by":[{"DOI":"10.1007\/s12185-017-2196-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000}}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2130-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2130-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2130-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T06:29:43Z","timestamp":1601188183000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2130-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["2130"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2130-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12185-017-2196-2","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}